



## Adalimumab Timeline




VENABLE | Fitzpatrick

## Adalimumab Challenged Claim Types in IPR and Litigation\*



VENABLE | Fitzpatrick


## Adalimumab IPR Status



VENABLE | Fitzpatrick


\*Considering IPR2017-00826 and IPR2017-01008 as one IPR, and IPR2017-00827 and IPR2017-01009 as one IPR.

## Adalimumab Method of Treatment Claim IPR Status



VENABLE | Fitzpatrick

## Adalimumab Formulation Claim IPR Status



VENABLE | Fitzpatrick

\*Considering IPR2017-00826 and IPR2017-01008 as one IPR, and IPR2017-00827 and IPR2017-01009 as one IPR.

FWD = Final Written Decision

**Technology:** Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor alpha (TNF $\alpha$ ). TNF $\alpha$  is a cytokine cell signaling protein that is involved in the inflammatory response that occurs in autoimmune diseases.

|           | <i>AbbVie v. Amgen</i><br>1:16-cv-00666 (D. Del.)<br>Settled  | <i>AbbVie v. Boehringer Ingelheim</i><br>1:17-cv-01065 (D. Del.)<br>Settled   | <i>Amgen v. AbbVie</i><br>IPR2015-01514<br>Institution denied   | <i>Amgen v. AbbVie</i><br>IPR2015-01517<br>Institution denied   |
|-----------|---|---|---|---|
| 8,663,945 | x   |   |   |   |
| 8,911,964 | x   |   |   |   |
| 8,916,157 | x   |   | x   |   |
| 8,916,158 |   |   |   | x   |
| 8,926,975 |   | x   |   |   |
| 8,961,973 | x   |   |   |   |
| 8,986,693 | x   |   |   |   |
| 9,018,361 |   | x   |   |   |
| 9,090,867 |   | x   |   |   |
| 9,096,666 | x   | x   |   |   |
| 9,220,781 | x   |   |   |   |
| 9,255,143 |   | x   |   |   |
| 9,266,949 |   | x   |   |   |
| 9,272,041 | x   | x   |   |   |
| 9,359,434 | x   |   |   |   |
| 9,365,645 | x   |   |   |   |
| 9,546,212 |   | x   |   |   |
|           | <i>Coherus v. AbbVie</i><br>IPR2016-00172<br>FWD: All claims unpatentable; Appeal No. 17-2304 pending with U.S. as Intervenor (Coherus settled) | <i>Boehringer Ingelheim v. AbbVie</i><br>IPR2016-00408, IPR2016-00409<br>FWD: All claims unpatentable; Appeal Nos. 17-2362 and 17-2363 pending with U.S. as Intervenor (Boehringer Ingelheim settled) | <i>Coherus v. AbbVie</i><br>IPR2016-00188<br>FWD: All claims unpatentable; Appeal No. 17-2305 pending with U.S. as Intervenor (Coherus settled) | <i>Coherus v. AbbVie</i><br>IPR2016-00189<br>FWD: All claims unpatentable; Appeal No. 17-2306 pending with U.S. as Intervenor (Coherus settled) |
| 8,889,135 | x   | x   |   |   |
| 9,017,680 |   |   | x   |   |
| 9,073,987 |   |   |   | x   |

|            | <i>Coherus v. AbbVie</i><br>IPR2017-00822, IPR2017-00823<br>Institution denied   | <i>Coherus v. AbbVie</i><br>IPR2017-00826 / IPR2017-01008<br>Institution denied                      | <i>Coherus v. AbbVie</i><br>IPR2017-00827 / IPR2017-01009<br>Institution denied                      |
|------------|--|--|--|
| 9,085,619  | x  | x  | x  |
|            | <i>Sandoz v. AbbVie</i><br>IPR2017-01823<br>Institution denied   | <i>Sandoz v. AbbVie</i><br>IPR2017-01987<br>Institution denied; Settled during request for rehearing | <i>Sandoz v. AbbVie</i><br>IPR2017-01988<br>Institution denied; Settled during request for rehearing |
| 8,802,100  | x  |  |  |
| 8,911,737  |  | x  |  |
| 8,974,790  |  |  | x  |
|            | <i>Sandoz v. AbbVie</i><br>IPR2017-02106<br>Settled after institution  | <i>Sandoz v. AbbVie</i><br>IPR2017-02105<br>Settled after institution                                | <i>Coherus v. AbbVie</i><br>IPR2016-01018<br>Institution denied                                      |
| 9,067,992  | x  |  |  |
| 9,090,689  |  | x  |  |
| 9,114,166  |  |  | x  |
|            | <i>Sandoz v. AbbVie</i><br>IPR2017-01824<br>Institution denied; Request for rehearing denied; Appeal No. 18-2142 settled |  | <i>Sandoz v. AbbVie</i><br>IPR2018-00002<br>Institution denied; Appeal No. 18-2143 settled           |
| 9,512,216  | x  |  | x  |
|            | <i>Sandoz v. AbbVie</i><br>IPR2018-00156<br>Institution denied   | <i>AbbVie v. Sandoz</i><br>3:18-cv-12668 (D.N.J.)<br>Settled   | <i>Coherus v. Amgen</i><br>[Related to Amjevita™]<br>1:19-cv-00139 (D. Del.)<br>Ongoing              |
| 9,187,559  | x  | x  |  |
| 9,750,808  |  | x  |  |
| 10,155,039 |  |  | x  |
| 10,159,732 |  |  | x  |
| 10,159,733 |  |  | x  |
| 10,207,000 |  |  | x  |

FWD = Final Written Decision